Edwards Lifesciences (NYSE:EW) Reaches New 12-Month High Following Analyst Upgrade

Shares of Edwards Lifesciences Corporation (NYSE:EW) reached a new 52-week high during mid-day trading on Friday after Royal Bank Of Canada raised their price target on the stock from $95.00 to $100.00. Royal Bank Of Canada currently has an outperform rating on the stock. Edwards Lifesciences traded as high as $87.61 and last traded at $87.4180, with a volume of 767415 shares trading hands. The stock had previously closed at $85.78.

A number of other equities analysts also recently commented on EW. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Evercore ISI increased their price objective on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Canaccord Genuity Group set a $89.00 price objective on shares of Edwards Lifesciences in a report on Friday. Finally, Oppenheimer cut shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $92.91.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the company. Level Four Advisory Services LLC increased its holdings in shares of Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 119 shares during the period. Colonial Trust Co SC boosted its stake in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after buying an additional 120 shares during the period. Parkside Financial Bank & Trust grew its holdings in shares of Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after buying an additional 130 shares during the last quarter. Prosperity Consulting Group LLC grew its holdings in shares of Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after buying an additional 132 shares during the last quarter. Finally, Howard Capital Management Inc. increased its position in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after acquiring an additional 132 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 2.3%

The stock has a market capitalization of $50.92 billion, a PE ratio of 37.85, a P/E/G ratio of 3.72 and a beta of 0.97. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $80.75 and a 200 day simple moving average of $78.68.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the company earned $0.67 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.